Eli Lilly, VCs Renew Osteoporosis Drug Push — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly is recruiting scientists for osteoporosis drug development, according to Bloomberg, after years of ceding the category.
- Merck, Novartis, and GSK each once had their own osteoporosis treatments that were sidelined by cumbersome dosing requirements and safety concerns.
- Biotech venture capitalists are now making bone health a funding priority, taking their cue from renewed pharma interest.
- A long-awaited regulatory change has been the key catalyst pulling drugmakers back into osteoporosis drug development.
- Other pharmaceutical companies are rumored to be rebuilding their osteoporosis pipelines alongside Eli Lilly.
- Many patients eligible for osteoporosis therapies currently take none of the available drugs, leaving a sizable unmet treatment need.
Why it matters: With a large pool of eligible osteoporosis patients going untreated and a regulatory shift lowering barriers, Eli Lilly's scientist hiring and the rumored follow-on from peers and VCs point to a competitive land grab in a dormant category. New therapies must win over patients who abandoned earlier drugs over dosing hassles and safety worries.
Ask SkimNews
